PAX8

Across TCGA pan-cancer cohorts, PAX8 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PAX8 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PAX8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PAX8 expression acts as an unfavorable survival marker.

LIHC, LUSC, and PRAD are the cancer types where PAX8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.127	0.786	<.001	15	view →
LUSC	DFS	Median	All	0.139	0.707	.022	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →
SKCM	OS	Median	III,IV	0.353	0.729	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PAX8–LIHC (OS)

Open the LIHC breakdown →